PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM

儿科肿瘤学集团--卡罗莱纳州联盟

• 批准号: 2009114
• 负责人: JOSEPH LAVER
• 金额: $ 15.62万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-06-15 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2009114
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; minimal residual disease; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tetrahydrofolylpolyglutamate synthase; tissue resource /registry; topotecan; trimetrexate; vincristine

DESCRIPTION (Adapted from the applicant's description): The institutions included in this proposal have been part of the Pediatric Oncology Group (POG) and received good performance scores during the past five years. There are two primary goals of this proposed research; the first is to accrue patients to the Group clinical trials in order to determine the optimal care of children with all types of cancers. The second is to contribute scientific expertise to the Group in areas of both patient care and tumor biology. This proposed research will allow participation in POG activities through a consortium effort of East Carolina University (ECU) School of Medicine, Carolinas Medical Center, Medical University of South Carolina (MUSC), Greenville Hospital, Presbyterian Hospital, and Memorial Mission Hospital (The Carolinas' Consortium). In addition to these clinical activities, their scientific efforts in next five years will include: (1) development of new protocols for the treatment of children with cancer focusing mainly on pediatric lymphomas; (2) expansion of studies of minimal marrow residual disease (using RT-PCR analysis) and assessment of new purging techniques in neuroblastoma; (3) participation in the laboratory evaluation of folylpolyglutamate synthetase (FPGS) in lymphoblasts of newly diagnosed patients; and (4) evaluation of the role hematopoietic growth factors in the treatment of pediatric malignancies.

描述（根据申请人的描述改编）：机构 该提案中包括小儿肿瘤学组的一部分 （POG）并在过去五年中获得了良好的性能得分。 这项拟议的研究有两个主要目标。首先是 将患者纳入小组临床试验，以确定 对所有类型的癌症儿童的最佳护理。 第二个是 在两个患者护理领域为小组贡献科学专业知识 和肿瘤生物学。 这项拟议的研究将允许参与POG 通过东卡罗来纳大学（ECU）的联盟努力的活动 南科罗尼亚州医学中心医学院医学院 卡罗来纳州（MUSC），格林维尔医院，长老会医院和纪念馆 宣教医院（卡罗来纳州的财团）。 除了这些临床 活动，他们未来五年的科学努力将包括：（1） 开发用于治疗癌症儿童的新方案 主要关注小儿淋巴瘤； （2）最小的研究扩展 骨髓残留疾病（使用RT-PCR分析）和新的评估 神经母细胞瘤的清除技术； （3）参加实验室 新近淋巴细胞中叶基聚谷氨酸合成酶（FPG）的评估 诊断患者； （4）评估造血生长的角色 小儿恶性肿瘤治疗的因素。